title: Ocular manifestations of Burkitt's lymphoma: experience in Ile-Ife south western Nigeria.
abstract: BACKGROUND
  Burkitt's lymphoma is the most common childhood tumour in subSaharan Africa that typically affects the jaws and abdomen. Ocular involvement with blindness has been documented in some studies.
  
  
  OBJECTIVE
  This was to evaluate the role of Burkitt's lymphoma (BL) as a cause of blindness in Nigerian children.
  
  
  METHODS
  Cases of BL seen in the hospital between 1986 and 2003 were studied retrospectively. Some of the patients with orbital disease at presentation underwent ultrasonographic examination of the eyes.
  
  
  RESULTS
  Forty-three (16.5%) of the 260 patients seen presented with orbital tumours; 29 (67.4 %) of the 43 patients had full ophthalmic examination. The patients studied comprised 22 males and 7 females with a M: F ratio of 3:1, and median(age range) of 7(3-15) years. Orbital tumours occurred concurrently with jaw masses on the same side in 19(65.5 %) of 29 patients; the eye diseases were unilateral in 23 (79.3%) and bilateral in six (20.7%) of the cases. Proptosis was the ocular presentation in 27(93%) of patients and it was associated with conjunctival injection in nine, chemosis in 11 and exposure keratopathy in five. Fourteen (48.3%) patients had associated blindness; 12 (85.7%) remained blind in the affected eye(s) and one regained vision to 6/36 after chemotherapy. The patients underwent Cyclophosphamide-Oncovin-Methotrexate (COM) regimen with intrathecal therapy. Eight (27.6%) patients had concomitant CNS disease; these included cases of 6th and 7th nerve palsies, one case of intra-cerebral extension of tumour and another case of total ophthalmoplegia.
  
  
  CONCLUSIONS
  Burkitt's lymphoma is an important cause of childhood blindness in Nigeria and the orbital disease ismainly extra ocular.
authors.affiliation: Department of Surgery (Ophthalmology Unit), Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria.
authors.forename: A O
authors.initials: AO
authors.lastname: Adeoye
authors.forename: M A
authors.initials: MA
authors.lastname: Durosinmi
authors.forename: O O
authors.initials: OO
authors.lastname: Adeodu
authors.forename: M B
authors.initials: MB
authors.lastname: Kagu
authors.forename: S O
authors.initials: SO
authors.lastname: Olateju
authors.forename: W A
authors.initials: WA
authors.lastname: Olowu
authors.forename: I L
authors.initials: IL
authors.lastname: Salawu
authors.forename: O D
authors.initials: OD
authors.lastname: Kazeem
mesh_terms: D000293:Adolescent; D000328:Adult; D001766:Blindness / Q000209:etiology; D002051:Burkitt Lymphoma / Q000150:complications* / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005094:Exophthalmos / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D005134:Eye Neoplasms / Q000209:etiology; D005260:Female; D005843:Geography; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D008727:Methotrexate